Lysophosphatidylinositol (LPI)

LPI is a proposed natural ligand and agonist of GPR55.1 LPI has recently been associated with mediating ovarian carcinoma cell-induced angiogenesis. The GPR 55 agonist, L-α-lysophosphatidylinositol, mediates ovarian carcinoma cell-induced angiogenesis.
Hofmann NA, Yang J, Trauger SA, Nakayama H, Huang L, Strunk D, Moses MA, Klagsbrun M, Bischoff J, Graier WF.
Br J Pharmacol. 2015 Aug;172(16):4107-18. doi: 10.1111/bph.13196. Epub 2015 Jun 26.
PMID: 25989290

Growing evidence points to a role of lysophosphatidylinositol (LPI) in cancer. L-α-lysophosphatidylinositol meets GPR55: a deadly relationship.
Ross RA.
Trends Pharmacol Sci. 2011 May;32(5):265-9. doi: 10.1016/ Epub 2011 Mar 1.
PMID: 21367464

External links

ChemIDplus #lysophosphatidylinositol

© 1999 - 2016 Copyright of